Cargando…
Anakinra or tocilizumab for prevention of COVID-19 death? A big dilemma
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Federation of Internal Medicine. Published by Elsevier B.V.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8179189/ https://www.ncbi.nlm.nih.gov/pubmed/34158235 http://dx.doi.org/10.1016/j.ejim.2021.05.039 |
| _version_ | 1783703727553642496 |
|---|---|
| author | Patoulias, Dimitrios Dimosiari, Athina Michailidis, Theodoros |
| author_facet | Patoulias, Dimitrios Dimosiari, Athina Michailidis, Theodoros |
| author_sort | Patoulias, Dimitrios |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8179189 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | European Federation of Internal Medicine. Published by Elsevier B.V. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-81791892021-06-05 Anakinra or tocilizumab for prevention of COVID-19 death? A big dilemma Patoulias, Dimitrios Dimosiari, Athina Michailidis, Theodoros Eur J Intern Med Letter to the Editor European Federation of Internal Medicine. Published by Elsevier B.V. 2021-08 2021-06-05 /pmc/articles/PMC8179189/ /pubmed/34158235 http://dx.doi.org/10.1016/j.ejim.2021.05.039 Text en © 2021 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Patoulias, Dimitrios Dimosiari, Athina Michailidis, Theodoros Anakinra or tocilizumab for prevention of COVID-19 death? A big dilemma |
| title | Anakinra or tocilizumab for prevention of COVID-19 death? A big dilemma |
| title_full | Anakinra or tocilizumab for prevention of COVID-19 death? A big dilemma |
| title_fullStr | Anakinra or tocilizumab for prevention of COVID-19 death? A big dilemma |
| title_full_unstemmed | Anakinra or tocilizumab for prevention of COVID-19 death? A big dilemma |
| title_short | Anakinra or tocilizumab for prevention of COVID-19 death? A big dilemma |
| title_sort | anakinra or tocilizumab for prevention of covid-19 death? a big dilemma |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8179189/ https://www.ncbi.nlm.nih.gov/pubmed/34158235 http://dx.doi.org/10.1016/j.ejim.2021.05.039 |
| work_keys_str_mv | AT patouliasdimitrios anakinraortocilizumabforpreventionofcovid19deathabigdilemma AT dimosiariathina anakinraortocilizumabforpreventionofcovid19deathabigdilemma AT michailidistheodoros anakinraortocilizumabforpreventionofcovid19deathabigdilemma |